Literature DB >> 15270846

Multiple antigenic peptides facilitate generation of anti-prion antibodies.

J Bainbridge1, N Jones, B Walker.   

Abstract

Recent reports have demonstrated the ability of anti-prion antibodies to inhibit PrPSc propagation. Due to the relatively poor immunogenic properties of both PrPC and PrPSc, the generation of anti-prion antibodies still causes a significant problem in the development of immunotherapeutic strategies. This study examines the potential of multiple antigenic peptides (MAPs) to raise an antibody response to prion derived sequences in mice. The MAP was constructed of a four spiked ring. Two spikes containing human or mouse derived prion amino acid sequences and two spikes containing the universally promiscuous tetanus toxoid sequence (aa 830-844) which was used to assist T-cell-dependent B-cell antibody production. Following vaccinations with the MAP or MAP plus adjuvant, sera were taken and antibody titres assessed. The MAP containing only the mouse sequence failed to elicit a significant antibody response. MAPs containing human prion sequences elicited antibody production to the corresponding prion sequence. Further analysis also demonstrated that these peptides were able to generate antibody responses that recognize conserved human and mouse sequences. These homologous sequences contain the heralded PrPSc specific sequence 'Tyr-Tyr-Arg' and therefore these MAPs may have some therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15270846      PMCID: PMC1809119          DOI: 10.1111/j.1365-2249.2004.02538.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  15 in total

1.  Antibodies inhibit prion propagation and clear cell cultures of prion infectivity.

Authors:  D Peretz; R A Williamson; K Kaneko; J Vergara; E Leclerc; G Schmitt-Ulms; I R Mehlhorn; G Legname; M R Wormald; P M Rudd; R A Dwek; D R Burton; S B Prusiner
Journal:  Nature       Date:  2001-08-16       Impact factor: 49.962

Review 2.  Interventional strategies against prion diseases.

Authors:  A Aguzzi; M Glatzel; F Montrasio; M Prinz; F L Heppner
Journal:  Nat Rev Neurosci       Date:  2001-10       Impact factor: 34.870

3.  Liposome entrapment and immunogenic studies of a synthetic lipophilic multiple antigenic peptide bearing VP1 and VP3 domains of the hepatitis A virus: a robust method for vaccine design.

Authors:  Isabel Haro; Silvia Pérez; Mónica García; Weng C Chan; Guadalupe Ercilla
Journal:  FEBS Lett       Date:  2003-04-10       Impact factor: 4.124

Review 4.  Technological advances in antigen delivery and synthetic peptide vaccine developmental strategies.

Authors:  C Olive; I Toth; D Jackson
Journal:  Mini Rev Med Chem       Date:  2001-11       Impact factor: 3.862

5.  Normal cellular prion protein is preferentially expressed on subpopulations of murine hemopoietic cells.

Authors:  T Liu; R Li; B S Wong; D Liu; T Pan; R B Petersen; P Gambetti; M S Sy
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

6.  Monoclonal antibodies inhibit prion replication and delay the development of prion disease.

Authors:  Anthony R White; Perry Enever; Mourad Tayebi; Rosey Mushens; Jackie Linehan; Sebastian Brandner; David Anstee; John Collinge; Simon Hawke
Journal:  Nature       Date:  2003-03-06       Impact factor: 49.962

7.  Generation of monoclonal antibodies against prion proteins with an unconventional nucleic acid-based immunization strategy.

Authors:  S Krasemann; T Jürgens; W Bodemer
Journal:  J Biotechnol       Date:  1999-08-20       Impact factor: 3.307

8.  Self prion protein peptides are immunogenic in Lewis rats.

Authors:  L Souan; R Margalit; O Brenner; I R Cohen; F Mor
Journal:  J Autoimmun       Date:  2001-12       Impact factor: 7.094

9.  Immunization delays the onset of prion disease in mice.

Authors:  Einar M Sigurdsson; David R Brown; Maki Daniels; Richard J Kascsak; Regina Kascsak; Richard Carp; Harry C Meeker; Blas Frangione; Thomas Wisniewski
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

10.  Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2.

Authors:  Krystyna Mozdzanowska; JinQi Feng; Mark Eid; Goran Kragol; Mare Cudic; Laszlo Otvos; Walter Gerhard
Journal:  Vaccine       Date:  2003-06-02       Impact factor: 3.641

View more
  3 in total

1.  Generation of antibodies against bovine recombinant prion protein in various strains of mice.

Authors:  Olga Andrievskaia; Heather McRae; Cathy Elmgren; Hongsheng Huang; Aru Balachandran; Klaus Nielsen
Journal:  Clin Vaccine Immunol       Date:  2006-01

Review 2.  Immunotherapy in prion disease.

Authors:  Yvonne Roettger; Yansheng Du; Michael Bacher; Inga Zerr; Richard Dodel; Jan-Philipp Bach
Journal:  Nat Rev Neurol       Date:  2012-12-18       Impact factor: 42.937

3.  H-ras protein in a bilayer: interaction and structure perturbation.

Authors:  Alemayehu A Gorfe; Arneh Babakhani; J Andrew McCammon
Journal:  J Am Chem Soc       Date:  2007-09-19       Impact factor: 15.419

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.